TY - JOUR
T1 - Long-term visual outcomes and histopathologic findings after cataract surgery in Ebola virus disease survivors in the Ebola virus RNA persistence in ocular tissues and fluids (EVICT) study
AU - Ebola Virus Persistence in Ocular Tissues Fluids (EVICT) Study Investigators
AU - Hartley, Caleb D.
AU - Kim, Lucas
AU - Fashina, Tolulope
AU - Begley, Jack
AU - Mattia, John G.
AU - Vandy, Matthew J.
AU - Harrison-Williams, Lloyd C.
AU - Mustapha, Jalikatu
AU - Garry, Robert F.
AU - Schieffelin, John S.
AU - Grant, Donald S.
AU - Goba, Augustine
AU - Kraft, Colleen S.
AU - Hayek, Brent R.
AU - Palacios, Gustavo
AU - Shantha, Jessica
AU - Crozier, Ian
AU - Zeng, Xiankun
AU - Yeh, Steven
N1 - Publisher Copyright:
© 2024, Public Library of Science. All rights reserved.
PY - 2024/11
Y1 - 2024/11
N2 - Background/Objectives Ebola virus disease (EVD) survivors develop post-acute ophthalmic sequelae, including a high prevalence of uveitis that may be complicated by vision-threatening cataract. After the non-detection of Ebola virus (EBOV) RNA in sampled ocular fluid, vision impairment due to cataract can be treated safely and effectively via manual small incision cataract surgery (MSICS). However, the long-term ocular visual outcomes and assessment of ocular tissues, including for genomic RNA, have been infrequently or not reported in Western African survivors. Subjects/Methods A cohort of EVD survivors with visually significant cataract, in whom EBOV RNA was not detected by RT-PCR testing of ocular fluid sampled prior to MSICS, were followed for a year after intraocular lens replacement. Ophthalmic outcomes, including visual acuity (VA), adverse events, and follow-up examinations, were recorded. Ocular tissue specimens obtained at MSICS underwent histopathologic examination and in-situ hybridization (ISH) targeting EBOV genomic RNA. Results Thirty-four EVD survivors underwent MSICS and were included for analysis. The median age of EVD survivors who underwent surgery at enrollment was 22.5 years (Interquartile range, IQR: 16.5–33) and the cohort was comprised of 20 females (58.8%). Median logMAR VA at preoperative baseline was 3 (IQR: 1–3) which improved to 0.4 (IQR: 0–0.6; n = 10; p = 0.002) and 0.6 (IQR: 0.18–0.78; n = 18; p < 0.0001) at 6-and 12-months following surgery, respectively. EBOV RNA was not detected in 7 cataract and capsular tissue specimens obtained at the time of MSICS. Conclusions After MSICS, meaningful improvement in vision was maintained in EVD survivors at longterm follow-up. EBOV RNA was not detected in cataract and lens capsule specimens, providing additional reassurance of the low risk of EBOV RNA exposure during cataract surgery. Further study is needed to understand long-term ocular outcomes, including adverse events, in this population.
AB - Background/Objectives Ebola virus disease (EVD) survivors develop post-acute ophthalmic sequelae, including a high prevalence of uveitis that may be complicated by vision-threatening cataract. After the non-detection of Ebola virus (EBOV) RNA in sampled ocular fluid, vision impairment due to cataract can be treated safely and effectively via manual small incision cataract surgery (MSICS). However, the long-term ocular visual outcomes and assessment of ocular tissues, including for genomic RNA, have been infrequently or not reported in Western African survivors. Subjects/Methods A cohort of EVD survivors with visually significant cataract, in whom EBOV RNA was not detected by RT-PCR testing of ocular fluid sampled prior to MSICS, were followed for a year after intraocular lens replacement. Ophthalmic outcomes, including visual acuity (VA), adverse events, and follow-up examinations, were recorded. Ocular tissue specimens obtained at MSICS underwent histopathologic examination and in-situ hybridization (ISH) targeting EBOV genomic RNA. Results Thirty-four EVD survivors underwent MSICS and were included for analysis. The median age of EVD survivors who underwent surgery at enrollment was 22.5 years (Interquartile range, IQR: 16.5–33) and the cohort was comprised of 20 females (58.8%). Median logMAR VA at preoperative baseline was 3 (IQR: 1–3) which improved to 0.4 (IQR: 0–0.6; n = 10; p = 0.002) and 0.6 (IQR: 0.18–0.78; n = 18; p < 0.0001) at 6-and 12-months following surgery, respectively. EBOV RNA was not detected in 7 cataract and capsular tissue specimens obtained at the time of MSICS. Conclusions After MSICS, meaningful improvement in vision was maintained in EVD survivors at longterm follow-up. EBOV RNA was not detected in cataract and lens capsule specimens, providing additional reassurance of the low risk of EBOV RNA exposure during cataract surgery. Further study is needed to understand long-term ocular outcomes, including adverse events, in this population.
UR - https://www.scopus.com/pages/publications/85212003261
U2 - 10.1371/journal.pntd.0012662
DO - 10.1371/journal.pntd.0012662
M3 - Article
C2 - 39576825
AN - SCOPUS:85212003261
SN - 1935-2727
VL - 2024-November
JO - PLoS Neglected Tropical Diseases
JF - PLoS Neglected Tropical Diseases
M1 - e0012662
ER -